Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06475937 · ClinicalTrials.gov registry record · Phase 1

A Study of DM001 in Patients With Advanced Solid Tumors

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Breast Neoplasms, sponsored by Xadcera Biopharmaceutical (Suzhou) Co..

Recruiting
Registry status
Phase 1
Development phase
128
Enrollment target
5
Study locations

NCT06475937 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Breast Neoplasms that is actively recruiting participants, run by Xadcera Biopharmaceutical (Suzhou) Co.. The registered enrollment target is 128 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06475937, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Breast Neoplasms, is actively recruiting participants, sponsored by Xadcera Biopharmaceutical (Suzhou) Co..

RECRUITING
Registry status
Phase 1
Development phase
128 participants
Enrollment target
5
Study locations

Study Summary

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. Participants will have up to 17 visits during the study.There will be up to a 4-week Screening Period followed by a treatment period that will be divided into 3-week cycles/ Participants will have 5 study visits during Cycle 1, 3 visits during Cycles 2 and 3, and 1 visit during subsequent cycles. Participants will have an End of Treatment visit 21 days (+ 7 days) after last dose of study drug and then a follow-up visit 30 days (± 7 days) after the End of Treatment visit.

Conditions Studied

Carcinoma, Non-Small Cell Lung Breast Neoplasms Solid Carcinoma

Interventions

  • DRUG DM001

Study Locations (5)

Queensland

  • Icon Cancer Centre South Brisbane - South Brisbane
  • Tasman Oncology Research - Southport

Tennessee

  • Sarah Cannon Research Institute (SCRI) - Nashville

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Victoria

  • Monash Health - Clayton

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2024-10-24
Est. Completion 2027-02-13
Phase Phase 1

Sponsor

Xadcera Biopharmaceutical (Suzhou) Co.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06475937

The ClinicalTrials.gov registry entry for NCT06475937 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower). The listed sponsor is Xadcera Biopharmaceutical (Suzhou) Co., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which DM001 is the first listed.

NCT06475937 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Queensland, Tennessee, Texas.

Frequently Asked Questions

What is clinical trial NCT06475937 about?

NCT06475937 is a clinical study titled "A Study of DM001 in Patients With Advanced Solid Tumors". The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. Participants will have up to 17 vis...

What is the current status of trial NCT06475937?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2024-10-24. Estimated completion is 2027-02-13.

What conditions does trial NCT06475937 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Breast Neoplasms, Solid Carcinoma.

What interventions are being tested in trial NCT06475937?

The interventions under investigation include: DM001 (DRUG).

Who is sponsoring clinical trial NCT06475937?

This trial is sponsored by Xadcera Biopharmaceutical (Suzhou) Co., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06475937 being conducted?

This trial has 5 study locations across Tennessee, Texas, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Breast Neoplasms

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.